ylaxis as the standard of care for all adults with VWD, regardless of subtype, represents a significant step forward in helping to manage bleeding risk and the burdens that bleeds can have on patients’ daily lives.”

This approval is based on data from three clinical trials – a Phase 3 trial in adults with VWD (NCT02973087), a Phase 3 study in children with VWD (NCT02932618) and a Phase 3b continuation trial in adults and children with VWD (NCT03879135) – as well as supportive real world data.1Please see the VONVENDIfull Prescribing Informationfor details on the established clinical profile.

“Children and adults living with VWD face unique challenges, including bleeds that can disrupt daily activities like school, work or spending time with loved ones, often leading to physical and emotional burdens,” said Cheryl Schwartz, Senior Vice President, U.S. Rare Disease Business Unit Lead and U.S. Commercial Operations at Takeda. “W
=*=*=*=*=*=
当前为第4/17页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页